Shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) have received a consensus rating of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $36.00.
Several research analysts have weighed in on DOVA shares. BidaskClub raised shares of Dova Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 24th. Zacks Investment Research raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. Leerink Swann lowered shares of Dova Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, July 9th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $40.00 target price on shares of Dova Pharmaceuticals in a research note on Sunday, July 15th.
Dova Pharmaceuticals stock opened at $18.41 on Friday. Dova Pharmaceuticals has a 12-month low of $18.17 and a 12-month high of $37.00. The stock has a market cap of $534.15 million, a P/E ratio of -13.15 and a beta of 0.87. The company has a quick ratio of 13.14, a current ratio of 13.19 and a debt-to-equity ratio of 0.17.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its earnings results on Thursday, August 9th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.07). The business had revenue of $4.58 million for the quarter. As a group, equities research analysts predict that Dova Pharmaceuticals will post -2.76 earnings per share for the current year.
In other news, CEO Alex Sapir bought 21,700 shares of Dova Pharmaceuticals stock in a transaction that occurred on Tuesday, August 14th. The shares were purchased at an average price of $22.83 per share, with a total value of $495,411.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 55.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in DOVA. Schwab Charles Investment Management Inc. increased its holdings in shares of Dova Pharmaceuticals by 36.4% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 13,500 shares of the company’s stock valued at $367,000 after acquiring an additional 3,600 shares during the period. Northern Trust Corp increased its holdings in shares of Dova Pharmaceuticals by 17.5% in the 1st quarter. Northern Trust Corp now owns 64,161 shares of the company’s stock valued at $1,740,000 after acquiring an additional 9,569 shares during the period. BlackRock Inc. increased its holdings in shares of Dova Pharmaceuticals by 12.5% in the 1st quarter. BlackRock Inc. now owns 648,614 shares of the company’s stock valued at $17,591,000 after acquiring an additional 71,815 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Dova Pharmaceuticals by 148.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after acquiring an additional 3,195 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Dova Pharmaceuticals in the 1st quarter valued at $220,000. 36.64% of the stock is currently owned by institutional investors and hedge funds.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Featured Article: What is a Fiduciary?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.